Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1980 1
1983 2
1984 1
1985 1
1986 2
1987 1
1988 3
1991 2
1992 1
1993 1
1995 1
1996 3
1997 1
1999 1
2000 1
2001 2
2002 1
2005 3
2006 3
2007 4
2008 2
2010 1
2013 2
2014 4
2015 8
2016 3
2017 2
2018 4
2019 3
2020 1
2021 3
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for edema allan
Your search for Deema Allan retrieved no results
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Diabetic Retinopathy Clinical Research Network, et al. N Engl J Med. 2015 Mar 26;372(13):1193-203. doi: 10.1056/NEJMoa1414264. Epub 2015 Feb 18. N Engl J Med. 2015. PMID: 25692915 Free PMC article. Clinical Trial.
BACKGROUND: The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of diabetic macular edema are unknown. METHODS: At 89 clinical sites, we randomly assigned 660 adults (mean age, 6110 years) with diabetic macular ed …
BACKGROUND: The relative efficacy and safety of intravitreous aflibercept, bevacizumab, and ranibizumab in the treatment of diabetic macular …
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
The major safety finding was amyloid-related imaging abnormalities with edema among patients receiving bapineuzumab, which increased with bapineuzumab dose and APOE epsilon4 allele number and which led to discontinuation of the 2.0-mg-per-kilogram dose. ...
The major safety finding was amyloid-related imaging abnormalities with edema among patients receiving bapineuzumab, which increased …
Mechanical ventilation in patients with cardiogenic pulmonary edema: a sub-analysis of the LUNG SAFE study.
Amado-Rodríguez L, Rodríguez-Garcia R, Bellani G, Pham T, Fan E, Madotto F, Laffey JG, Albaiceta GM; LUNG SAFE investigators. Amado-Rodríguez L, et al. J Intensive Care. 2022 Dec 25;10(1):55. doi: 10.1186/s40560-022-00648-x. J Intensive Care. 2022. PMID: 36567347 Free PMC article.
BACKGROUND: Patients with acute respiratory failure caused by cardiogenic pulmonary edema (CPE) may require mechanical ventilation that can cause further lung damage. ...
BACKGROUND: Patients with acute respiratory failure caused by cardiogenic pulmonary edema (CPE) may require mechanical ventilation th …
A novel frameshift mutation in Allan-Herndon-Dudley syndrome.
Liu Z, Zhao S, Chen J, Ma L, Shi Q, Zhou Y. Liu Z, et al. Int J Legal Med. 2022 Jul;136(4):1181-1187. doi: 10.1007/s00414-022-02823-z. Epub 2022 Apr 7. Int J Legal Med. 2022. PMID: 35391604
Allan-Herndon-Dudley syndrome (AHDS) is a very rare, X-linked psychomotor disability syndrome with delayed myelination, almost exclusively affecting boys. ...Compared with a normally developing 4-year-old boy, the deceased showed cerebral atrophy and cerebral edema, …
Allan-Herndon-Dudley syndrome (AHDS) is a very rare, X-linked psychomotor disability syndrome with delayed myelination, almost exclus …
The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness.
Dennis M, Sandercock P, Graham C, Forbes J; CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration; Smith J. Dennis M, et al. Health Technol Assess. 2015 Sep;19(76):1-90. doi: 10.3310/hta19760. Health Technol Assess. 2015. PMID: 26418530 Free PMC article. Clinical Trial.
EXCLUSION CRITERIA: age < 16 years; subarachnoid haemorrhage; and contra-indications to IPC including dermatitis, leg ulcers, severe oedema, severe peripheral vascular disease and congestive cardiac failure. ...

EXCLUSION CRITERIA: age < 16 years; subarachnoid haemorrhage; and contra-indications to IPC including dermatitis, leg ulcers, severe o

…
Pulmonary oedema of immersion.
Koehle MS, Lepawsky M, McKenzie DC. Koehle MS, et al. Sports Med. 2005;35(3):183-90. doi: 10.2165/00007256-200535030-00001. Sports Med. 2005. PMID: 15730335 Review.
Acute pulmonary oedema has been described in individuals participating in three aquatic activities: (i) scuba diving; (ii) breath-hold diving; and (iii) endurance swimming. ...Radiography is the investigation of choice, demonstrating typical findings for pulmonary oedem …
Acute pulmonary oedema has been described in individuals participating in three aquatic activities: (i) scuba diving; (ii) breath-hol …
Pulmonary oedema following exercise in humans.
Hodges AN, Mayo JR, McKenzie DC. Hodges AN, et al. Sports Med. 2006;36(6):501-12. doi: 10.2165/00007256-200636060-00004. Sports Med. 2006. PMID: 16737343 Review.
A limited number of studies have been completed with the specific purpose of identifying pulmonary oedema following exercise or a similar intervention. Of these, approximately 50% have observed a positive change and the remaining have provided results that are either incon …
A limited number of studies have been completed with the specific purpose of identifying pulmonary oedema following exercise or a sim …
Evidence for and Against Genetic Predispositions to Acute and Chronic Altitude Illnesses.
MacInnis MJ, Koehle MS. MacInnis MJ, et al. High Alt Med Biol. 2016 Dec;17(4):281-293. doi: 10.1089/ham.2016.0024. Epub 2016 Aug 8. High Alt Med Biol. 2016. PMID: 27500591 Review.
Evidence to support a genetic basis for susceptibilities to acute mountain sickness (AMS) and high-altitude cerebral edema (HACE) is limited, owing partially to the subjective and unclear phenotype of AMS and the rarity and severity of HACE. In contrast, recent genomic stu …
Evidence to support a genetic basis for susceptibilities to acute mountain sickness (AMS) and high-altitude cerebral edema (HACE) is …
Topical nepafenec in eyes with noncentral diabetic macular edema.
Friedman SM, Almukhtar TH, Baker CW, Glassman AR, Elman MJ, Bressler NM, Maker MP, Jampol LM, Melia M; Diabetic Retinopathy Clinical Research Network. Friedman SM, et al. Retina. 2015 May;35(5):944-56. doi: 10.1097/IAE.0000000000000403. Retina. 2015. PMID: 25602634 Free PMC article. Clinical Trial.
PURPOSE: To evaluate the effect of a topical, nonsteroidal antiinflammatory drug, nepafenac 0.1%, in eyes with noncentral diabetic macular edema. METHODS: Multicenter, double-masked randomized trial. Individuals with good visual acuity and noncentral-involved diabetic macu …
PURPOSE: To evaluate the effect of a topical, nonsteroidal antiinflammatory drug, nepafenac 0.1%, in eyes with noncentral diabetic macular …
Outcome of Treatment of Uveitic Macular Edema: The Multicenter Uveitis Steroid Treatment Trial 2-Year Results.
Tomkins-Netzer O, Lightman S, Drye L, Kempen J, Holland GN, Rao NA, Stawell RJ, Vitale A, Jabs DA; Multicenter Uveitis Steroid Treatment Trial Research Group. Tomkins-Netzer O, et al. Ophthalmology. 2015 Nov;122(11):2351-9. doi: 10.1016/j.ophtha.2015.07.036. Epub 2015 Sep 7. Ophthalmology. 2015. PMID: 26359188 Free PMC article. Clinical Trial.
MAIN OUTCOME MEASURES: Improvement in macular edema (20% reduction in central point thickness on OCT), resolution of macular edema (normalization of thickness on OCT), and best-corrected visual acuity (BCVA). ...CONCLUSIONS: About two thirds of eyes with uveitic mac …
MAIN OUTCOME MEASURES: Improvement in macular edema (20% reduction in central point thickness on OCT), resolution of macular edema …
67 results